S&P 500
(-0.34%) 5 018.39 points
Dow Jones
(0.23%) 37 903 points
Nasdaq
(-0.33%) 15 605 points
Oil
(0.13%) $79.10
Gas
(0.31%) $1.938
Gold
(1.00%) $2 334.00
Silver
(1.04%) $27.03
Platinum
(1.25%) $966.80
USD/EUR
(0.03%) $0.933
USD/NOK
(-0.07%) $11.02
USD/GBP
(-0.07%) $0.798
USD/RUB
(0.06%) $93.51

リアルタイムの更新: Consun Pharmaceutical [1681.HK]

取引所: HKSE セクター: Pharmaceuticals 産業: Drug Manufacturers—Specialty & Generic
最終更新日時30 4月 2024 @ 17:08

1.04% HKD 5.85

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 17:08):

Consun Pharmaceutical Group Limited, an investment holding company, researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People's Republic of China...

Stats
本日の出来高 1.10M
平均出来高 766 851
時価総額 4.68B
EPS HKD0 ( 2024-03-28 )
Last Dividend HKD0.300 ( 2023-06-08 )
Next Dividend HKD0 ( N/A )
P/E 5.52
ATR14 HKD0.00700 (0.12%)

ボリューム 相関

長: -0.10 (neutral)
短: 0.41 (neutral)
Signal:(57.617) Neutral

Consun Pharmaceutical 相関

10 最も正の相関
10 最も負の相関

知っていましたか?

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Consun Pharmaceutical 相関 - 通貨/商品

The country flag 0.36
( neutral )
The country flag 0.59
( weak )
The country flag 0.00
( neutral )
The country flag 0.49
( neutral )
The country flag -0.59
( weak negative )

Consun Pharmaceutical 財務諸表

Annual 2023
収益: HKD2.59B
総利益: HKD1.92B (74.19 %)
EPS: HKD0.980
FY 2023
収益: HKD2.59B
総利益: HKD1.92B (74.19 %)
EPS: HKD0.980
FY 2022
収益: HKD2.34B
総利益: HKD1.76B (75.35 %)
EPS: HKD0.860
FY 2021
収益: HKD2.04B
総利益: HKD1.53B (74.70 %)
EPS: HKD0.740

Financial Reports:

No articles found.

Consun Pharmaceutical Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
HKD0
(N/A)
HKD0
(N/A)
HKD0
(N/A)
HKD0.300
(N/A)
HKD0
(N/A)
HKD0
(N/A)
HKD0
(N/A)
HKD0
(N/A)
HKD0
(N/A)
HKD0
(N/A)

Consun Pharmaceutical Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 9.21 - good (92.12%) | Divividend Growth Potential Score: 6.75 - Stable (35.02%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information
First Dividend HKD0.0480 2014-09-25
Last Dividend HKD0.300 2023-06-08
Next Dividend HKD0 N/A
Payout Date 0000-00-00
Next Payout Date N/A
# dividends 19 --
Total Paid Out HKD2.25 --
Avg. Dividend % Per Year 0.00% --
Score 3.58 --
Div. Sustainability Score 9.21
Div.Growth Potential Score 6.75
Div. Directional Score 7.98 --
Next Divdend (Est)
(2024-06-24)
HKD0.334 Estimate 3.45 %
Dividend Stability
0.28 Very Poor
Dividend Score
3.58
Pay Frequency
Semi-Annually
Yearly Payout
Year Amount Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for HKSE

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
2318.HK Ex Dividend Knight 2023-09-11 Semi-Annually 0 0.00%
1286.HK Ex Dividend Knight 2023-08-21 Semi-Annually 0 0.00%
0347.HK No Dividend Player 2023-06-01 Sporadic 0 0.00%
6099.HK Ex Dividend Junior 2023-07-14 Annually 0 0.00%
1848.HK Ex Dividend Junior 2023-09-07 Semi-Annually 0 0.00%
0874.HK Ex Dividend Knight 2023-06-14 Annually 0 0.00%
0023.HK Ex Dividend Knight 2023-09-07 Semi-Annually 0 0.00%
2660.HK Ex Dividend Knight 2023-06-30 Annually 0 0.00%
1425.HK Ex Dividend Junior 2023-06-16 Annually 0 0.00%
0512.HK Ex Dividend Knight 2023-06-09 Annually 0 0.00%

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM0.3031.5003.945.91[0 - 0.5]
returnOnAssetsTTM0.1421.2005.256.30[0 - 0.3]
returnOnEquityTTM0.2271.5008.5910.00[0.1 - 1]
payoutRatioTTM0.265-1.0007.35-7.35[0 - 1]
currentRatioTTM2.860.8000.6920.554[1 - 3]
quickRatioTTM2.570.80010.008.00[0.8 - 2.5]
cashRatioTTM1.8381.5000.8981.347[0.2 - 2]
debtRatioTTM0.0921-1.5008.46-10.00[0 - 0.6]
interestCoverageTTM01.000-1.111-1.111[3 - 30]
operatingCashFlowPerShareTTM0.3162.009.8910.00[0 - 30]
freeCashFlowPerShareTTM0.2952.009.8510.00[0 - 20]
debtEquityRatioTTM0.140-1.5009.44-10.00[0 - 2.5]
grossProfitMarginTTM0.7421.0000.9680.968[0.2 - 0.8]
operatingProfitMarginTTM0.3191.0005.625.62[0.1 - 0.6]
cashFlowToDebtRatioTTM0.5011.0008.338.33[0.2 - 2]
assetTurnoverTTM0.4700.800-0.198-0.159[0.5 - 2]
Total Score9.21

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM5.441.0009.550[1 - 100]
returnOnEquityTTM0.2272.509.1010.00[0.1 - 1.5]
freeCashFlowPerShareTTM0.2952.009.9010.00[0 - 30]
dividendYielPercentageTTM8.491.50010.000[0 - 0.4]
operatingCashFlowPerShareTTM0.3162.009.8910.00[0 - 30]
payoutRatioTTM0.2651.5007.35-7.35[0 - 1]
pegRatioTTM1.1991.5005.340[0.5 - 2]
operatingCashFlowSalesRatioTTM0.09811.000-0.04860[0.1 - 0.5]
Total Score6.75

Consun Pharmaceutical

Consun Pharmaceutical Group Limited, an investment holding company, researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People's Republic of China. The company operates through two segments, Consun Pharmaceutical and Yulin Pharmaceutical. It offers uremic clearance granule to treat chronic kidney diseases; Yishen Huashi particles to treat proteinuria; Gadopentetate Dimeglumine injections for magnetic resonance image diagnostics of nervous centralis, stomach, chest, pelvic cavity, and extremities, as well as for renal function assessment; and Iopamidol injections used for neuroradiology, angiography, and urography. The company also provides Yuanli Kang, an iron-dextrin oral solution; Yibao Yua, an erythromycin estolate suspension; Yuantong Ning, a cetirizine hydrochloride oral solution; and Zhixueling capsules to treat hysteromyoma bleeding, prolonged lochiorrhea, intermenstrual bleeding, bleeding after use of a contraceptive ring, hemorrhoidal bleeding, and epistaxis. In addition, it offers Gyn Antidysmenorrheic tablets for the treatment of irregular menstruation, irregular period during perimenopause, and abdominal pain during menstruation due to hepatic depression and blood deficiency; and Antibacterial Fujie lotion for staphylococcus aureus, Candida albicans, and escherichia coli in the feminine vaginal. Further, the company provides bone-setting liquid; Yunxiang analgesic tincture for treatment of rheumatism, common cold, headache, stomachache, cardiodynia, and pain in gastral cavity and chilblain; Sanqi Chuangchun capsules for activating blood circulation and dispersing blood stasis; and Shiduqing capsules and tablets, and Paeonol ointment for skin disease. Additionally, it offers hepatobiliary, gastroenterology, tonics, and other medicines. The company was founded in 1997 and is headquartered in Guangzhou, the People's Republic of China.

について ライブシグナル

このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。